The Anastrozole-Induced Bone Loss (ARIBON) trial likewise demonstrated improvements in bone mineral density at the hip and spine (4.5% higher than placebo for hip and 6.2% higher than placebo for spine) with ibandronate (150 mg orally, every 28 days); in addition,ibandronate improved serum levels of NTX, CTX-I, bone AP, as well as T-score. Oral clodronate(1600 mg per day) also led to a significant improvement in bone mineral density at the hip, spine, and femoral neck among postmenopausal patients.